Clinical Trial Update: A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safe dose of BI 891065 alone and in combination with BI 754091 in patients with incurable or metastatic tumors was terminated, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Non-small-cell Lung
• Neoplasm Metastasis
• Neoplasms

Drugs mentioned

• BI 891065
• BI-754091

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms, Neoplasm Metastasis | Phase 1 | Status: TERMINATED | Results posted: 2024-11-19